A Tetra Bio-Pharma and IntelGenx Combine for New Drug Development

A Tetra Bio-Pharma and IntelGenx Combine for New Drug Development
A Tetra Bio-Pharma and IntelGenx Combine for New Drug Development
N/A by N/A is licensed under N/A

Under the binding term sheet, Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the U.S. and Canada. The U.S. cancer pain market is expected to reach $5 billion in 2018.

Per the Binding Term Sheet, Tetra will make a non-refundable exclusive negotiation payment to IntelGenx, an upfront payment along with set milestone payments based on the completion of an efficacy study, approvals from FDA and Health Canada and launching of the product.

IntelGenx will be responsible for the research and development of the product, including clinical studies and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the application and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the drug product.

 

For the full press release go to Financial Content


Read More
Tags
Biotechs/Pharma, Cannabis News, Domestic - Medicinal, Health
Thumbnail Photo Credit: N/A by N/A is licensed under N/A N/A